{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:34:30Z","timestamp":1782963270498,"version":"3.54.5"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118718","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:06:47Z","timestamp":1771891607000},"page":"118718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["PROTACs as novel therapeutics against Mycobacterium tuberculosis: Current progress and future directions"],"prefix":"10.1016","volume":"308","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-3700","authenticated-orcid":false,"given":"Deepthi","family":"Ramesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahammed Ameen","family":"Thottasseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118718_bib1","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c02386","article-title":"Nanoenabling MbtI inhibitors for next-generation tuberculosis therapy","author":"Cazzaniga","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib2","first-page":"355","article-title":"First-in-class pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones against leishmaniasis and tuberculosis: Rationale, in vitro, ex vivo studies and mechanistic insights","author":"Ramesh","year":"2022","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2026.118718_bib3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/35085034","article-title":"Mycobacterium tuberculosis: here today, and here tomorrow","volume":"2","author":"Russell","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118718_bib4","doi-asserted-by":"crossref","first-page":"e1372","DOI":"10.1016\/S2214-109X(21)00299-0","article-title":"Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the sustainable development goals tuberculosis targets: a full-income analysis","volume":"9","author":"Silva","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ejmech.2026.118718_bib5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1128\/JCM.01287-16","article-title":"Mycobacterial taxonomy","volume":"55","author":"Forbes","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118718_bib6","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1128\/JCM.01172-11","article-title":"Species Distribution of the Mycobacterium tuberculosis complex in clinical isolates from 2007 to 2010 in Turkey: a prospective study","volume":"49","author":"Bayraktar","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118718_bib7","first-page":"437","article-title":"Microbe profile: mycobacterium tuberculosis: humanity's deadly microbial foe","volume":"164","author":"Gordon","year":"2018","journal-title":"Microbiology (N. Y.)"},{"key":"10.1016\/j.ejmech.2026.118718_bib8","series-title":"World Health Organization","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118718_bib9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","article-title":"Anti-tuberculosis treatment strategies and drug development: challenges and priorities","volume":"20","author":"Dartois","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118718_bib10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cmi.2023.07.013","article-title":"Recent advances in the treatment of tuberculosis","volume":"30","author":"Motta","year":"2024","journal-title":"Clin. Microbiol. Infection"},{"key":"10.1016\/j.ejmech.2026.118718_bib11","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118718_bib12","first-page":"729","article-title":"The diagnosis and treatment of tuberculosis","volume":"116","author":"Su\u00e1rez","year":"2019","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.ejmech.2026.118718_bib13","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.cmi.2024.06.016","article-title":"Candidate anti-tuberculosis medicines and regimens under clinical evaluation","volume":"30","author":"Hoelscher","year":"2024","journal-title":"Clin. Microbiol. Infection"},{"key":"10.1016\/j.ejmech.2026.118718_bib14","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1128\/AAC.05708-11","article-title":"SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis","volume":"56","author":"Tahlan","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118718_bib15","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jac\/dki319","article-title":"Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines","volume":"56","author":"Protopopova","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2026.118718_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"PanACEA consortium, high-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118718_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2007.04.005","article-title":"The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria","volume":"26","author":"Leach","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118718_bib18","series-title":"Oxazolidinone Compound and Methods of Use Thereof as an Antibacterial Agent","year":"2021"},{"key":"10.1016\/j.ejmech.2026.118718_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101213","article-title":"Sanfetrinem, an oral \u03b2-lactam antibiotic repurposed for the treatment of tuberculosis","volume":"80","author":"Ram\u00f3n-Garc\u00eda","year":"2025","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2026.118718_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0732-8893(96)00173-3","article-title":"In vitro activity of sanfetrinem (GV104326), a new trinem antimicrobial agent, versus Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis","volume":"26","author":"Doern","year":"1996","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118718_bib21","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.bmc.2019.02.026","article-title":"3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel","volume":"27","author":"Sutherland","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00945-24","article-title":"TBAJ-587, a novel diarylquinoline, is active against Mycobacterium abscessus, antimicrob","volume":"68","author":"Fan","year":"2024","journal-title":"Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118718_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01412-21","article-title":"Comparative efficacy of the novel diarylquinoline TBAJ-876 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis","volume":"65","author":"Almeida","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118718_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01294-22","article-title":"Cyclic AMP-mediated inhibition of cholesterol catabolism in Mycobacterium tuberculosis by the novel drug candidate GSK2556286, antimicrob","volume":"67","author":"Brown","year":"2023","journal-title":"Agents Chemother"},{"key":"10.1016\/j.ejmech.2026.118718_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00132-22","article-title":"GSK2556286 is a novel antitubercular drug candidate effective In Vivo with the potential to shorten tuberculosis treatment","volume":"66","author":"Nuermberger","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118718_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00035-23","article-title":"Next-generation diarylquinolines improve sterilizing activity of regimens with pretomanid and the novel oxazolidinone TBI-223 in a mouse tuberculosis model","volume":"67","author":"Li","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118718_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01655-22","article-title":"Side-by-Side profiling of oxazolidinones to estimate the therapeutic window against mycobacterial infections","volume":"67","author":"Negatu","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118718_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01542-24","article-title":"Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants, Antimicrob","volume":"69","author":"Lombardi","year":"2025","journal-title":"Agents Chemother"},{"key":"10.1016\/j.ejmech.2026.118718_bib29","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1128\/AAC.00778-15","article-title":"The 8-Pyrrole-Benzothiazinones are noncovalent inhibitors of DprE1 from","volume":"59","author":"Makarov","year":"2015","journal-title":"Mycobacterium tuberculosis, Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118718_bib30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/emmm.201303575","article-title":"Towards a new combination therapy for tuberculosis with next generation benzothiazinones","volume":"6","author":"Makarov","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2026.118718_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00448-22","article-title":"Synergistic effect of Q203 combined with PBTZ169 against Mycobacterium tuberculosis","volume":"66","author":"Nguyen","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118718_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00583-21","article-title":"Comparative analysis of pharmacodynamics in the C3HeB\/FeJ mouse tuberculosis model for DprE1 inhibitors TBA-7371, PBTZ169, and OPC-167832","volume":"65","author":"Robertson","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118718_bib33","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41591-024-02829-7","article-title":"A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial","volume":"30","author":"Diacon","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118718_bib34","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1021\/acs.jmedchem.7b00631","article-title":"Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)","volume":"60","author":"Li","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib35","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nm.3262","article-title":"Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis","volume":"19","author":"Pethe","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118718_bib36","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/JCM.00274-17","article-title":"In Vitro susceptibility testing of tedizolid against nontuberculous mycobacteria","volume":"55","author":"Brown-Elliott","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118718_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01939-18","article-title":"In Vitro activity of tedizolid against Mycobacterium tuberculosis, antimicrob","volume":"63","author":"Ruiz","year":"2019","journal-title":"Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118718_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00149-25","article-title":"Sudapyridine (WX-081) inhibits Mycobacterium tuberculosis by targeting ATP synthase and upregulating host innate immunity","volume":"10","author":"Li","year":"2025","journal-title":"mSphere"},{"key":"10.1016\/j.ejmech.2026.118718_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02477-21","article-title":"Sudapyridine (WX-081), a novel compound against Mycobacterium tuberculosis","volume":"10","author":"Yao","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.ejmech.2026.118718_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.118718_bib41","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41589-024-01624-2","article-title":"PROTAC-ing tuberculosis","volume":"20","author":"Preti","year":"2024","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118718_bib42","article-title":"Recent advances in PROTAC-based antiviral strategies","volume":"11","author":"Ahmad","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ejmech.2026.118718_bib43","author":"Wu"},{"key":"10.1016\/j.ejmech.2026.118718_bib44","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.118718_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543776.2021.1840553","article-title":"The therapeutic potential of PROTACs","volume":"31","author":"Benowitz","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.118718_bib46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","article-title":"The dTAG system for immediate and target-specific protein degradation","volume":"14","author":"Nabet","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118718_bib47","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1021\/acs.jmedchem.1c00895","article-title":"Molecular glues for targeted protein degradation: from serendipity to rational discovery","volume":"64","author":"Dong","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib48","doi-asserted-by":"crossref","first-page":"9278","DOI":"10.1021\/acs.jmedchem.3c00449","article-title":"Molecular glue discovery: current and future approaches","volume":"66","author":"Dewey","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib49","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.cell.2017.10.033","article-title":"A method for the acute and rapid degradation of endogenous proteins","volume":"171","author":"Clift","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118718_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113247","article-title":"Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy","volume":"216","author":"Ma","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib51","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/01.STR.0000126891.93919.4e","article-title":"Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy","volume":"35","author":"Wojcik","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.ejmech.2026.118718_bib52","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/17460441.2019.1659242","article-title":"PROTACs\u2013 a game-changing technology","volume":"14","author":"Konstantinidou","year":"2019","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118718_bib53","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.trsl.2020.03.007","article-title":"New tuberculosis drug targets, their inhibitors, and potential therapeutic impact","volume":"220","author":"Shetye","year":"2020","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejmech.2026.118718_bib54","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jac\/dkx506","article-title":"Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care","volume":"73","author":"Dookie","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2026.118718_bib55","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/resp.13393","article-title":"Drug resistance mechanisms and drug susceptibility testing for tuberculosis","volume":"23","author":"Miotto","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.ejmech.2026.118718_bib56","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00204-016-1727-6","article-title":"Antibiotic resistance mechanisms in M. Tuberculosis: an update","volume":"90","author":"Nguyen","year":"2016","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejmech.2026.118718_bib57","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.1021\/acs.jmedchem.2c00227","article-title":"Tuberculosis drug discovery: challenges and new Horizons","volume":"65","author":"Fernandes","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib58","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/ng.3767","article-title":"Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance","volume":"49","author":"Manson","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2026.118718_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001880","article-title":"Evolution of extensively drug-resistant tuberculosis over four decades: whole genome sequencing and dating analysis of Mycobacterium tuberculosis isolates from KwaZulu-Natal","volume":"12","author":"Cohen","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejmech.2026.118718_bib60","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1128\/JCM.43.7.3114-3120.2005","article-title":"Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient","volume":"43","author":"Meacci","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118718_bib61","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/femsre\/fuz016","article-title":"Cell wall peptidoglycan in Mycobacterium tuberculosis : an Achilles' heel for the TB-causing pathogen","volume":"43","author":"Maitra","year":"2019","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2026.118718_bib62","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2217\/fmb-2017-0135","article-title":"Cell envelope lipids in the pathophysiology of Mycobacterium Tuberculosis","volume":"13","author":"Singh","year":"2018","journal-title":"Future Microbiol."},{"key":"10.1016\/j.ejmech.2026.118718_bib63","doi-asserted-by":"crossref","first-page":"18867","DOI":"10.1074\/jbc.M116.739227","article-title":"Assembling of the Mycobacterium tuberculosis cell wall core","volume":"291","author":"Grzegorzewicz","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1194923","article-title":"Mycobacterium tuberculosis cell-wall and antimicrobial peptides: a mission impossible?","volume":"14","author":"Jacobo-Delgado","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118718_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119301","article-title":"Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs","volume":"274","author":"Chauhan","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2026.118718_bib66","doi-asserted-by":"crossref","first-page":"32244","DOI":"10.1021\/acsomega.3c02563","article-title":"Overcoming Mycobacterium tuberculosis drug resistance: novel medications and repositioning strategies","volume":"8","author":"Sachan","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.118718_bib67","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural mechanism for rifampicin inhibition of bacterial RNA polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118718_bib68","series-title":"Tuberculosis: Pathogenesis, Protection, and Control","year":"1994"},{"key":"10.1016\/j.ejmech.2026.118718_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.00681","article-title":"New insights in to the intrinsic and acquired drug resistance mechanisms in mycobacteria","volume":"8","author":"Nasiri","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118718_bib70","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.3390\/ijms24065202","article-title":"Tuberculosis: pathogenesis, current treatment regimens and new drug targets","volume":"24","author":"Alsayed","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118718_bib71","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1042\/BCJ20230191","article-title":"Targeting bacterial degradation machinery as an antibacterial strategy","volume":"480","author":"Petkov","year":"2023","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2026.118718_bib72","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.micinf.2009.08.003","article-title":"The Mycobacterium tuberculosis proteasome: more than just a barrel-shaped protease","volume":"11","author":"Cerda-Maira","year":"2009","journal-title":"Microb. Infect."},{"key":"10.1016\/j.ejmech.2026.118718_bib73","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1365-2958.2005.05036.x","article-title":"Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate","volume":"59","author":"Hu","year":"2006","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118718_bib74","first-page":"1104","article-title":"Ubiquitin-like protein involved in the proteasome pathway of Mycobacterium tuberculosis","volume":"322","author":"Pearce","year":"2008","journal-title":"Science (1979)"},{"key":"10.1016\/j.ejmech.2026.118718_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-58073-1","article-title":"Substrates bind to residues lining the ring of asymmetrically engaged bacterial proteasome activator bpa","volume":"16","author":"von Rosen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118718_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010058","article-title":"Microbial proteasomes as drug targets","volume":"17","author":"Zhang","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2026.118718_bib77","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1074\/jbc.RA117.001471","article-title":"Proteasome substrate capture and gate opening by the accessory factor PafE from Mycobacterium tuberculosis","volume":"293","author":"Hu","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib78","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1512094113","article-title":"Structural analysis of the dodecameric proteasome activator PafE in Mycobacterium tuberculosis","volume":"113","author":"Bai","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.118718_bib79","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.str.2016.10.008","article-title":"Structural analysis of the bacterial proteasome activator bpa in complex with the 20S proteasome","volume":"24","author":"Bolten","year":"2016","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.118718_bib80","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nature08357","article-title":"Inhibitors selective for mycobacterial versus human proteasomes","volume":"461","author":"Lin","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118718_bib81","doi-asserted-by":"crossref","first-page":"9968","DOI":"10.1021\/ja400021x","article-title":"N,C-capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets","volume":"135","author":"Lin","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.118718_bib82","doi-asserted-by":"crossref","first-page":"9246","DOI":"10.1021\/acs.jmedchem.9b01187","article-title":"Selective Phenylimidazole-Based inhibitors of the Mycobacterium tuberculosis proteasome","volume":"62","author":"Zhan","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib83","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1021\/acs.jmedchem.1c00296","article-title":"Macrocyclic peptides that selectively inhibit the Mycobacterium tuberculosis proteasome","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib84","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1021\/acsinfecdis.6b00172","article-title":"Rational design of selective and bioactive inhibitors of the Mycobacterium tuberculosis proteasome","volume":"3","author":"Totaro","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118718_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002511","article-title":"Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection","volume":"8","author":"Raju","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2026.118718_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53736-8","article-title":"Molecular and structural insights into an asymmetric proteolytic complex (ClpP1P2) from Mycobacterium smegmatis","volume":"9","author":"Nagpal","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118718_bib87","author":"Poulton"},{"key":"10.1016\/j.ejmech.2026.118718_bib88","article-title":"Structural insights into bortezomib-induced activation of the caseinolytic chaperone-protease system in Mycobacterium tuberculosis","volume":"16","author":"Zhou","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118718_bib89","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/emboj.2012.5","article-title":"The active ClpP protease from M. tuberculosis is a complex composed of a heptameric ClpP1 and a ClpP2 ring","volume":"31","author":"Akopian","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2026.118718_bib90","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1417120111","article-title":"Crystal structure of Mycobacterium tuberculosis ClpP1P2 suggests a model for peptidase activation by AAA+ partner binding and substrate delivery","volume":"111","author":"Schmitz","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.118718_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125345","article-title":"The Mycobacterium tuberculosis ClpP1P2 protease interacts asymmetrically with its ATPase partners ClpX and ClpC1","volume":"10","author":"Leodolter","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118718_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060228","article-title":"Mycobacterium tuberculosis ClpP proteases are Co-transcribed but exhibit different substrate specificities","volume":"8","author":"Personne","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118718_bib93","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/nm1306","article-title":"Dysregulation of bacterial proteolytic machinery by a new class of antibiotics","volume":"11","author":"Br\u00f6tz-Oesterhelt","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118718_bib94","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1128\/JB.06142-11","article-title":"Validation of the essential ClpP protease in Mycobacterium tuberculosis as a novel drug target","volume":"194","author":"Ollinger","year":"2012","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.ejmech.2026.118718_bib95","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/mmi.13362","article-title":"Acyldepsipeptide antibiotics kill mycobacteria by preventing the physiological functions of the ClpP1P2 protease","volume":"101","author":"Famulla","year":"2016","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118718_bib96","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00253-15","article-title":"Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria","volume":"6","author":"Moreira","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.ejmech.2026.118718_bib97","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.chembiol.2014.01.014","article-title":"Lassomycin, a ribosomally synthesized cyclic peptide, kills Mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2","volume":"21","author":"Gavrish","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118718_bib98","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1002\/anie.201101740","article-title":"The natural product cyclomarin kills Mycobacterium Tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease","volume":"50","author":"Schmitt","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.118718_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-023-04658-9","article-title":"ClpC2 protects mycobacteria against a natural antibiotic targeting ClpC1-dependent protein degradation","volume":"6","author":"Taylor","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2026.118718_bib101","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02204-18","article-title":"Rufomycin targets ClpC1 proteolysis in Mycobacterium tuberculosis and M. abscessus","volume":"63","author":"Choules","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118718_bib99","doi-asserted-by":"crossref","first-page":"30883","DOI":"10.1074\/jbc.M113.493767","article-title":"Structural basis of mycobacterial inhibition by Cyclomarin A","volume":"288","author":"Vasudevan","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib102","doi-asserted-by":"crossref","first-page":"536","DOI":"10.15252\/embj.201695028","article-title":"Mycobacterium tuberculosis protease MarP activates a peptidoglycan hydrolase during acid stress","volume":"36","author":"Botella","year":"2017","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2026.118718_bib103","doi-asserted-by":"crossref","first-page":"12489","DOI":"10.1074\/jbc.M113.456541","article-title":"Substrate specificity of MarP, a periplasmic protease required for resistance to acid and oxidative stress in Mycobacterium tuberculosis","volume":"288","author":"Small","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib104","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1021\/cb500746z","article-title":"Target-based screen against a periplasmic serine protease that regulates intrabacterial ph homeostasis in mycobacterium tuberculosis","volume":"10","author":"Zhao","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118718_bib105","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118718_bib106","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Molecular Biomedicine"},{"key":"10.1016\/j.ejmech.2026.118718_bib107","doi-asserted-by":"crossref","DOI":"10.1021\/acs.biochem.4c00577","article-title":"Journey of PROTAC: from bench to clinical trial and beyond","author":"Berkley","year":"2025","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.118718_bib108","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC technology: opportunities and challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118718_bib109","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.118718_bib110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118718_bib111","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/17460441.2023.2178413","article-title":"PROTAC antibiotics: the time is now","volume":"18","author":"Sarathy","year":"2023","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118718_bib112","author":"Sakamoto"},{"key":"10.1016\/j.ejmech.2026.118718_bib113","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/2472555220965528","article-title":"E3 ligase ligands for PROTACs: how they were found and how to discover new ones","volume":"26","author":"Ishida","year":"2021","journal-title":"SLAS Discovery"},{"key":"10.1016\/j.ejmech.2026.118718_bib114","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118718_bib115","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRASG12Cby VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2026.118718_bib116","unstructured":"K.A. Rutherford, K.J. Mcmanus, Running Title: Expanding the Utility of Protacs, (n.d. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0747\/3403039\/mct-23-0747.pdf."},{"key":"10.1016\/j.ejmech.2026.118718_bib117","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1535-7163.MCT-23-0747","article-title":"PROTACs: current and future potential as a precision medicine strategy to combat cancer","volume":"23","author":"Rutherford","year":"2024","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118718_bib118","first-page":"273","article-title":"Current strategies for the design of PROTAC linkers: a critical review, explor. Target","volume":"1","author":"Troup","year":"2020","journal-title":"Antitumor Ther."},{"key":"10.1016\/j.ejmech.2026.118718_bib119","doi-asserted-by":"crossref","first-page":"20930","DOI":"10.1021\/acs.jmedchem.5c01479","article-title":"Harnessing chimeric degrader technologies for antimicrobial innovation","volume":"68","author":"Poddar","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib120","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118718_bib121","first-page":"32","article-title":"Targeted protein degradation for infectious diseases: from basic biology to drug discovery, ACS bio and","volume":"3","author":"Espinoza-Ch\u00e1vez","year":"2023","journal-title":"Med Chem Au"},{"key":"10.1016\/j.ejmech.2026.118718_bib122","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3390\/biomedicines10092100","article-title":"Targeted protein degradation to overcome resistance in cancer therapies: PROTAC and N-Degron pathway","volume":"10","author":"Kim","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.118718_bib123","first-page":"1963","article-title":"The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide","volume":"302","author":"Darwin","year":"2003","journal-title":"Science (1979)"},{"key":"10.1016\/j.ejmech.2026.118718_bib124","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1021\/acsinfecdis.7b00231","article-title":"Targeting the proteostasis network for mycobacterial drug discovery","volume":"4","author":"Lupoli","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118718_bib125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1741-7007-10-95","article-title":"The pupylation pathway and its role in mycobacteria","volume":"10","author":"Barandun","year":"2012","journal-title":"BMC Biol."},{"key":"10.1016\/j.ejmech.2026.118718_bib126","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bbamcr.2013.03.022","article-title":"Pupylation as a signal for proteasomal degradation in bacteria","volume":"1843","author":"Striebel","year":"2014","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.ejmech.2026.118718_bib127","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-46218-7","article-title":"Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug-resistant mycobacteria","volume":"15","author":"Junk","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118718_bib128","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15516-1","article-title":"Pyrazinamide triggers degradation of its target aspartate decarboxylase","volume":"11","author":"Gopal","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118718_bib129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pbiomolbio.2019.11.005","article-title":"Targeted protein degradation in antibacterial drug discovery?","volume":"152","author":"Gopal","year":"2020","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118718_bib130","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cell.2022.05.009","article-title":"BacPROTACs mediate targeted protein degradation in bacteria","volume":"185","author":"Morreale","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118718_bib131","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.cell.2022.05.026","article-title":"BacPROTACs to basics: targeted protein degradation in bacteria","volume":"185","author":"Burslem","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118718_bib132","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.cell.2023.04.009","article-title":"Clp-targeting BacPROTACs impair mycobacterial proteostasis and survival","volume":"186","author":"Hoi","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118718_bib133","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","article-title":"Proteolysis-targeting chimeras with reduced off-targets","volume":"16","author":"Nguyen","year":"2024","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1505255","article-title":"Precision-engineered PROTACs minimize off-tissue effects in cancer therapy","volume":"11","author":"Shi","year":"2024","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2026.118718_bib135","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00924-z","article-title":"Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118718_bib136","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.118718_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107984","article-title":"Design and optimization strategies of PROTACs and its application, comparisons to other targeted protein degradation for multiple oncology therapies","volume":"154","author":"Malarvannan","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.669762","article-title":"Applications of bacterial degrons and degraders \u2014 toward targeted protein degradation in bacteria","volume":"8","author":"Izert","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2026.118718_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117858","article-title":"Harnessing caseinolytic proteases ClpP1P2 for next-generation antimycobacterial agents: mechanisms, challenges and opportunities","volume":"296","author":"Bonjorno","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib140","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01703-4","article-title":"Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs","volume":"18","author":"Mamun","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118718_bib141","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.chembiol.2024.01.002","article-title":"Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor","volume":"31","author":"Su","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118718_bib142","doi-asserted-by":"crossref","first-page":"18040","DOI":"10.1021\/acs.jmedchem.5c01019","article-title":"Small-molecule ligands targeting lysosome-shuttling receptors and the emerging landscape of lysosome-targeting chimeras","volume":"68","author":"Yang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118718_bib143","article-title":"A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy","volume":"16","author":"Xiao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118718_bib144","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1039\/D3CS00344B","article-title":"Targeted protein degradation directly engaging lysosomes or proteasomes","volume":"53","author":"Kim","year":"2024","journal-title":"Chem. Soc. Rev."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T21:12:16Z","timestamp":1779743536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426001637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":144,"alternative-id":["S0223523426001637"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118718","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PROTACs as novel therapeutics against Mycobacterium tuberculosis: Current progress and future directions","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118718"}}